ELIZABETH C. REED, M.D.; PAULA S. DANDLIKER, M.S.N.; JOEL D. MEYERS, M.D.
Effective treatment for cytomegalovirus pneumonia, a major cause of mortality in marrow transplant patients, remains elusive. A new acyclic nucleoside, 9-[2-hydroxy-1-(hydroxy methyl) ethoxy methyl] guanine (DHPG; BW B759U, Burroughs-Wellcome, Research Triangle Park, North Carolina) has been shown to have both in-vitro and in-vivo activity against cytomegalovirus but did not improve survival when used to treat cytomegalovirus pneumonia in marrow transplant recipients, although it caused a significant reduction in the amount of virus in lung tissue (1). Because the progressive pulmonary failure may have resulted from a persistent inflammatory response in the lung induced by the virus, we used DHPG combined
REED EC, DANDLIKER PS, MEYERS JD. Treatment of Cytomegalovirus Pneumonia with 9-[2-Hydroxy-1-(Hydroxymethyl) ethoxymethyl] Guanine and High-Dose Corticosteroids. Ann Intern Med. 1986;105:214–215. doi: 10.7326/0003-4819-105-2-214
Download citation file:
Published: Ann Intern Med. 1986;105(2):214-215.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use